CP and Decreased liver function: The unpredictable events associated with moderate liver dysfunction led to a different survival distribution among patients with CP B and those with CP A. In the GIDEON study, the survival distribution of treatment‐naive patients with CP B treated with sorafenib could be modeled using an exponential distribution function (Figure 2).46